Chronic Lymphocytic Leukemia CLL Mutations Detection Comprehensive Panel
Understanding Chronic Lymphocytic Leukemia Genetic Testing
Chronic Lymphocytic Leukemia (CLL) represents the most common adult leukemia in Western countries, characterized by the accumulation of mature-looking lymphocytes in the blood, bone marrow, and lymphoid tissues. The CLL Mutations Detection Comprehensive Panel represents a revolutionary advancement in precision oncology, providing comprehensive genetic profiling essential for modern CLL management.
This sophisticated molecular diagnostic test utilizes advanced PCR-MLPA technology to analyze multiple genetic markers simultaneously, offering clinicians unprecedented insights into disease biology, prognosis, and therapeutic opportunities. The comprehensive nature of this panel makes it an indispensable tool for personalized treatment planning in CLL patients.
What This Test Measures and Detects
The CLL Mutations Detection Comprehensive Panel examines 14 critical genetic biomarkers that significantly impact disease behavior and treatment response:
Key Gene Mutations Analyzed:
- SF3B1 K700E mutation – Associated with poor prognosis and treatment resistance
- MYD88 L265P mutation – Often indicates more favorable disease course
- NOTCH1 p.2514 fs mutation – Linked to aggressive disease and transformation risk
- PTEN loss at 10q23.31 – Important for cell signaling pathway alterations
Chromosomal Abnormalities Assessed:
- 11q deletion – High-risk feature requiring aggressive treatment
- 17p deletion – Worst prognostic marker, associated with chemoimmunotherapy resistance
- 13q14 deletion – Favorable prognostic indicator when isolated
- Trisomy 12 – Intermediate risk category marker
- 14q deletion – Additional chromosomal abnormality assessment
- Trisomy 19 – Rare but significant chromosomal finding
- Chromosome 2p gain – Emerging prognostic marker
- 6q deletion – Associated with disease progression
- 8p loss & 8q amplification – Complex chromosomal changes
- 9p21 loss – Important cell cycle regulator deletion
Who Should Consider This Comprehensive CLL Panel?
This advanced genetic testing is recommended for individuals who:
- Have been newly diagnosed with Chronic Lymphocytic Leukemia
- Are experiencing unexplained symptoms including fatigue, night sweats, or unexplained weight loss
- Have persistent lymphocytosis or enlarged lymph nodes
- Require treatment planning and selection guidance
- Need prognostic stratification for disease management
- Are experiencing disease progression or transformation
- Require monitoring of genetic evolution during treatment
Clinical Indications Include:
- Initial diagnostic workup for CLL classification
- Risk stratification before treatment initiation
- Guidance for targeted therapy selection (BTK inhibitors, BCL-2 antagonists)
- Assessment of eligibility for clinical trials
- Monitoring for clonal evolution and resistance development
Significant Benefits of Comprehensive CLL Genetic Testing
Personalized Treatment Planning
The comprehensive genetic profile obtained through this panel enables oncologists to tailor treatment strategies specifically to your genetic makeup. Patients with 17p deletion or TP53 mutations may benefit from novel agents like BTK inhibitors rather than traditional chemotherapy, significantly improving outcomes.
Accurate Prognostic Assessment
Understanding your specific genetic markers provides crucial prognostic information. Patients with isolated 13q deletion typically have excellent long-term outcomes, while those with 17p deletion require more aggressive management and closer monitoring.
Informed Therapeutic Decisions
The detection of specific mutations guides the selection of targeted therapies. MYD88 mutations may respond better to certain treatment regimens, while NOTCH1 mutations might indicate higher risk of Richter’s transformation, requiring different monitoring strategies.
Early Intervention Opportunities
Identifying high-risk genetic features early allows for proactive management and timely intervention, potentially preventing disease complications and improving quality of life.
Understanding Your Test Results
Favorable Genetic Profile
Patients with isolated 13q deletion or MYD88 mutations typically have more indolent disease courses and may qualify for watchful waiting approaches rather than immediate treatment.
Intermediate Risk Findings
Trisomy 12 or normal karyotype results generally indicate intermediate prognosis, requiring regular monitoring and standard treatment approaches when indicated.
High-Risk Genetic Features
The presence of 17p deletion, 11q deletion, or TP53 mutations signifies high-risk disease requiring specialized management with novel targeted agents and closer clinical surveillance.
Mutation-Specific Implications
Specific gene mutations carry distinct clinical implications. SF3B1 mutations often correlate with unmutated IGHV status and poorer outcomes, while NOTCH1 mutations increase transformation risk to aggressive lymphoma.
Test Pricing and Details
| Test Feature | Details |
|---|---|
| Test Name | Chronic Lymphocytic Leukemia CLL Mutations Detection Comprehensive Panel |
| Regular Price | $376 USD |
| Discount Price | $226 USD |
| Turnaround Time | Sample by Monday 11 AM, Report by Saturday |
| Sample Type | 4 mL (2 mL min.) whole blood from 1 Lavender top (EDTA) tube |
| Shipping Instructions | Ship refrigerated. DO NOT FREEZE |
| Required Documentation | Duly filled Genomics Clinical Information Requisition Form (Form 20) |
| Testing Methodology | PCR – MLPA (Multiplex Ligation-dependent Probe Amplification) |
Nationwide Accessibility
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, Austin, Jacksonville, Fort Worth, Columbus, San Francisco, and many more cities nationwide.
Take Control of Your CLL Journey Today
Understanding your genetic profile is the first step toward personalized, effective CLL management. Our comprehensive testing provides the critical information needed to make informed treatment decisions and optimize your care pathway.
Ready to gain comprehensive insights into your CLL genetic profile? Our dedicated team is available to answer your questions and schedule your testing. Contact us today to begin your personalized cancer management journey.
Call or WhatsApp: +1(267) 388-9828 to book your Comprehensive CLL Mutations Detection Panel or to speak with our genetic counseling specialists.
Don’t leave your treatment decisions to chance. Empower yourself with comprehensive genetic information designed to guide your CLL management strategy and improve your treatment outcomes.